

Fluoguide Q4 2022 - Slightly shifted timelines but equity story remains unchanged

Redeye comments on Fluoguide's Q4 2022 report as we enter a catalyst-rich 2023e for the company. Fluoguide recently announced a slight delay in phase IIb HGG top-line data, though we judge that the company's equity story remains unchanged following the news.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Fluoguide Q4 2022 - Slightly shifted timelines but equity story remains unchanged